{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-018773","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.700051+00:00","generated_at":"2026-06-03T05:30:08.638131+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"X4 Pharma receives FDA approval for XOLREMDI (mavorixafor), first drug for WHIM syndrome","bullets":["XOLREMDI approved for patients 12+ with WHIM syndrome to increase circulating neutrophils and lymphocytes.","Phase 3 4WHIM trial met primary endpoint (TAT-ANC) vs. placebo (p<0.0001).","XOLREMDI showed 60% reduction in annualized infection rate vs. placebo.","X4 granted Rare Pediatric Disease Priority Review Voucher concurrent with approval.","U.S. commercial launch via specialty pharmacy PANTHERx Rare; X4Connect patient support launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-018773","json":"https://secwatch.observer/filing/0001628280-24-018773.json","markdown":"https://secwatch.observer/filing/0001628280-24-018773.md","text":"https://secwatch.observer/filing/0001628280-24-018773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024018773/0001628280-24-018773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024018773/xfor-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:30:08.638131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}